CN109557320A - The kit of auxiliary detection Placenta acrreta and its application - Google Patents
The kit of auxiliary detection Placenta acrreta and its application Download PDFInfo
- Publication number
- CN109557320A CN109557320A CN201811418592.3A CN201811418592A CN109557320A CN 109557320 A CN109557320 A CN 109557320A CN 201811418592 A CN201811418592 A CN 201811418592A CN 109557320 A CN109557320 A CN 109557320A
- Authority
- CN
- China
- Prior art keywords
- vegf
- detection
- concentration
- reagent
- pregnant woman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Abstract
The reagent that the present invention will detect VEGF-A concentration is applied to detection maternal blood, using the VEGF-A concentration of Peripheral Blood before giving a birth of normal labor pregnant and lying-in women as reference value, the peripheral blood of pregnant woman to be checked is detected value, value/reference value be will test using 1.0 as cutoff value, the kit for assisting detection Placenta acrreta is prepared, it has the differentiation performance of moderate strength not only for the pregnant woman of Placenta acrreta and normal labor pregnant woman, and pregnant woman for Placenta acrreta and use other methods auxiliary diagnosis result that there is the differentiation performance of moderate strength for the pregnant woman of false positive.The kit provides one kind and easily and efficiently assists detection means, and the concentration data detected can be conducive to the accuracy for improving pregnant women placental implantation Risk Screening with the result binding analysis of other methods as reference value.
Description
Technical field
The invention belongs to technical field of molecular biology, in particular to the kit of a kind of auxiliary detection Placenta acrreta and its
Using.
Background technique
Placenta acrreta refers to the villus intrusion part mesometrium of placenta, and the crisscross dispersion of placental villi is implanted into uterine muscular
A kind of disease, be a kind of rare but critical complication of obstetrics, can cause the big bleeding of patient, shock, the perforation of uterus and
Infection, in addition it is dead.It is 4/1000 that Placenta acrreta is reported in the incidence in pregnant and lying-in women in recent years, and wherein placental presentation merges tire
High, the clinical amount of bleeding of disk implantation incidence is big, the death rate is high, referred to as fierce dangerous Placenta acrreta.
Clinically still lack Placenta acrreta early screening or aided diagnosis technique before simple and effective childbirth at present, thus
Caused processing delay is the key that lead to one of its serious Averse pregnancy outcomes.Since Placenta acrreta lacks typically antenatal
Clinical manifestation, sign and lab index, pre-natal diagnosis is highly difficult, and it is true to prove to carry out finally to need puerperal pathological diagnosis
It examines.
During noninvasive serological screening method is further being researched and developed, it is bright to have been reported that discovery Serum AFP has with Placenta acrreta
Aobvious correlation, but its specificity is not high, not yet exploitation is at clinical adaptable detection kit.In pregnant early-time analysis motherhood
Placenta free mRNA in woman's blood plasma can predict Placenta acrreta, but very high for technological means requirement, there is no clinic at present
Using.In addition, studies have reported that fetus dissociative DNA increases in Placenta acrreta pregnant and lying-in women's peripheral blood in blood plasma, but clinic is anticipated
It is adopted and indefinite.Therefore, at present there is no for clinical application, using in maternal blood biomarker auxiliary detection placenta
The method of implantation.
Summary of the invention
Based on this, the purpose of the present invention is to provide a kind of kits of auxiliary detection Placenta acrreta, for detecting parent
Biomarker VEGF-A in blood is the antenatal of Placenta acrreta in order to provide a kind of method of Placenta acrreta auxiliary detection
Diagnosis provides reference data.
To achieve the above object, the present invention provides the following technical scheme that
A kind of kit of auxiliary detection Placenta acrreta, includes the reagent for detecting VEGF-A concentration.
The present invention also provides a kind of method of auxiliary detection Placenta acrreta, specific technical solution is as follows:
A kind of aided detection method of Placenta acrreta, comprising the following steps:
Sampling: maternal blood sample to be checked is acquired respectively；
It prepares standard curve: using the VEGF-A standard items of the reagent detection gradient concentration of detection VEGF-A concentration, drawing
Standard curve；
Detection: maternal blood sample to be checked is detected using the reagent of detection VEGF-A concentration, is calculated by standard curve
Obtain the VEGF-A concentration in maternal blood sample to be checked.
Based on the above-mentioned technical proposal, the present invention has the effect that
The reagent that the present invention will detect VEGF-A concentration is applied to detection maternal blood, with normal labor pregnant and lying-in women
The VEGF-A concentration of Peripheral Blood is reference value before giving a birth, and the peripheral blood of pregnant woman to be checked is detected value, will test value/reference value with
1.0 be used as cutoff value, be prepared for assist detection Placenta acrreta kit, not only for Placenta acrreta pregnant woman with
Normal labor pregnant woman has a differentiation performance of moderate strength, and pregnant woman for Placenta acrreta and is examined using other methods auxiliary
Disconnected result is that the pregnant woman of false positive has the differentiation performance of moderate strength.The kit provides one kind and easily and efficiently assists
Detection means, the concentration data detected can be conducive to improve pregnant as reference value with the result binding analysis of other methods
The accuracy of woman's Placenta acrreta Risk Screening.
Detailed description of the invention
Fig. 1-6 is the pregnant woman of normal pregnant woman and postpartum definitive pathological diagnosis with Placenta acrreta in the non-of the preceding acquisition of childbirth
The result of anticoagulation cirumferential blood serum progress VEGF-A Concentration Testing；
Fig. 7-8 is that ultrasound is diagnosed as that pregnant woman and the disease of Placenta acrreta does not occur after placental presentation but childbirth before giving a birth
Reason makes a definite diagnosis the non-anticoagulation cirumferential blood serum that the pregnant woman for merging Placenta acrreta with placental presentation acquires before childbirth and carries out VEGF-A
The result of Concentration Testing；
Fig. 9-10 is normal labor or other complication occurs but pregnant woman and the disease of Placenta acrreta do not occur
Reason makes a definite diagnosis the non-anticoagulation cirumferential blood serum that the pregnant woman for merging Placenta acrreta with placental presentation acquires before childbirth and carries out VEGF-A
The result of Concentration Testing.
Specific embodiment
To facilitate the understanding of the present invention, it below with reference to embodiment to invention is more fully described, is given below
Presently preferred embodiments of the present invention.But the present invention can be realized with many different forms, however it is not limited to described herein
Embodiment.Purpose of providing these embodiments is makes the disclosure of the present invention more thorough and comprehensive.It should be understood that
In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition, for example (,) Sambrook et al., molecule gram
It is grand: condition described in laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989),
Or according to the normal condition proposed by manufacturer.Used various common agents, are commercial product in embodiment.
Unless otherwise defined, all technical and scientific terms used herein and belong to technical field of the invention
The normally understood meaning of technical staff is identical.Used term is intended merely to describe specific reality in the description of the invention
Apply the purpose of example, it is not intended that in the limitation present invention.Term as used herein "and/or" includes one or more relevant institutes
Any and all combinations of list of items.
The present invention provides a kind of kits of auxiliary detection Placenta acrreta, include the reagent for detecting VEGF-A concentration,
The reagent is used to detect the VEGF-A concentration in maternal blood, also includes VEGF-A standard items in kit.Wherein one
In a little embodiments, the VEGF-A detection reagent in kit is VEGF-A MBP enzyme linked immuno-adsorbent assay reagent, VEGF-A chemistry hair
Light immunologic function test reagent.Preferably, the VEGF-A detection reagent is Bio-Plex Assay 171AC600M.
The present invention also provides a kind of aided detection method of Placenta acrreta, step includes:
Sampling: maternal blood sample to be checked is acquired respectively；
It prepares standard curve: using the VEGF-A standard items of the reagent detection gradient concentration of detection VEGF-A concentration, drawing
Standard curve；
Detection: maternal blood sample to be checked is detected using the reagent of detection VEGF-A concentration, is calculated by standard curve
Obtain the VEGF-A concentration in maternal blood sample to be checked.
Wherein, the sampling may also include acquisition normal labor peripheral blood sample；Peripheral blood is non-anticoagulation cirumferential blood serum,
After acquisition, 900 × g~1100 × g is centrifuged 9~11min, it is preferable that is centrifuged 10min in 1000 × g, removes blood platelet and sink
Starch.If acquisition after cannot detect at once, can be saved in ultra low temperature freezer, ultra low temperature freezer temperature setting for -70 DEG C~-
85℃。
In addition, the aided detection method of Placenta acrreta, further includes: detect normal pregnancies periphery using VEGF-A detection reagent
Blood sample calculates to obtain VEGF-A concentration in the maternal blood sample by standard curve；Calculate maternal blood to be checked
The ratio of the VEGF-A concentration in VEGF-A concentration and normal pregnancies peripheral blood sample in sample；Antenatal for Placenta acrreta is examined
It is disconnected that reference data is provided.Its ratio is greater than 1.0, the method that should be taken a step forward in pregnant woman childbirth through iconography detection, in conjunction with
Above-mentioned reference data is predicted, is judged.The doubtful person of Placenta acrreta height should reinforce clinical monitoring as early as possible, and prevention is serious bad pregnant
It is pregnent final result.
In wherein some embodiments, the VEGF-A detection reagent are as follows: VEGF-A MBP enzyme linked immuno-adsorbent assay reagent,
VEGF-A chemiluminescence immunoassay detection reagent.Preferably, the reagent of the detection VEGF-A concentration is Bio-Plex Assay
171AC600M。
Embodiment 1
One, material and equipment
Kit: Bio-Plex Assay 171AC600M；Instrument model: Bio-Plex 200；Vortex mixed instrument；It is applicable in
1.5-2ml the refrigerated centrifuge of centrifuge tube；Microplate oscillator (revolving speed that 500rpm can be reached)；Magnetic Isolation plate (Hand-
Held Magnetic Plate Washer)；2 μ l-1000 μ l single track pipettors；20 μ l-300 μ l multichannel pipettors；Multiple tracks is moved
Liquid device reservoir；Deionized water, beaker, test tube, blotting paper etc..
Two, peripheral blood sample is acquired
After informed consent, acquired respectively before childbirth suspected case non-anticoagulation cirumferential blood serum and 30-50 normal point
The non-anticoagulation cirumferential blood serum of pregnant and lying-in women is given birth to, is solidified at room temperature 30-45 minutes, 4 DEG C of 1000g are centrifuged 15 minutes, are then shifted
Into cryogenic vial.It freezes in -80 DEG C of ultra low temperature freezers.After to sample collection, 4 DEG C of 50 μ l serum of freeze thawing, 1000g weight
It is centrifuged 10 minutes again, to completely remove blood platelet and other sediments.
Three, blood serum designated object of the verifying VEGF-A as auxiliary detection Placenta acrreta
1, Sample Dilution:
According to the ratio distilled water dilute serum sample of 1:4, using the VEGF- of Quality Control qualification producer such as Bio-Plex
A detection kit detects the VEGF-A concentration of all samples on same plate to specifications.
2, reagent dilutions:
Wash buffer (10 × → 1 ×): it is diluted with ddH2O 9:1.
Beads (50 × → 1 ×): Beads is vortexed 30s, and every 50 × Beads of pipe takes out 100 μ L, 1 × wash is added
Buffer to final volume 5mL is mixed.
Detection Antibody (50 × → 1 ×): every 50 × Detection of pipe Antibody takes out 60ul, adds
Enter detection antibodydiluent to final volume 3mL, mixes.
3, standard items are dissolved
(1) standard items are taken out, 2000 × g is centrifuged 10s；
(2) the Universal Assay Buffer of 50 μ L is respectively added into standard quality control；
(3) 30s is mixed gently；
(4) it is placed in 5-10min on ice；
(5) standard items are mixed into a pipe, Universal Assay Buffer is added, it is final to obtain 250 μ L mixing
Standard items.
4, the dilution (4 times) of standard items
8 union of PCR provided in kit is taken out for dilution standard product；
The hybrid standard product of 200 μ L are added into the first pipe as standard items 1；
1 × Universal Assay Buffer of 150 μ L is separately added into pipe 2-8；
From taking 50 μ L hybrid standard product to be added in pipe 2 in pipe 1,10 mixings of piping and druming, avoid the generation of bubble as far as possible up and down；
The pipette tips more renewed are transferred in pipe 3 from the dilution standard product for drawing 50 μ L in pipe 2, up and down 10 mixings of piping and druming.
It successively shifts, completes the gradient dilution of hybrid standard product,；
It is placed in spare on ice.
5, prepare microballoon
(1) vortex microballoon 30s；
(2) 50 μ L premix microballoon is added in every hole into 96 orifice plates.
(3) 96 orifice plates are put into Magnetic Isolation plate, it is ensured that orifice plate is by stuck fast.To the static 2min of plate, make microballoon heavy
Bottom.Then magnetic sheet is quickly inverted, pours out the liquid in orifice plate.96 orifice plates can not be taken from Magnetic Isolation plate during this
Out；
(4) the Wash Buffer of 150 μ L 1X is added into every hole, stands 30s, then magnetic sheet is inverted, pours out orifice plate
In liquid；
(5) in the state of inversion, with the residual liquid of paper handkerchief absorption orifice surface.
6, microballoon and sample incubation
(1) the Universal Assay Buffer of 25 μ L is separately added into every hole；
(2) standard items or sample of 25 μ L are separately added into the hole of Xiang Zhiding；
(3) 25 μ L Universal Assay Buffer are added into blank control；
(4) orifice plate sealer, 500rpm shakes at room temperature is incubated for 30min, stands overnight in 4 degree.It takes out within second day, 500rpm
Concussion is incubated for 30min at room temperature.
7, board-washing
(1) 96 orifice plates are placed in Magnetic Isolation plate, stand 2min；
(2) sealer is gently removed, liquid splash is avoided；
(3) the liquid inversion in orifice plate is removed；
(4) 150 μ L 1X Wash Buffer are added into every hole, stand 30s, the liquid inversion in orifice plate is removed.Weight
Multiple step, is washed 3 times altogether；
(5) at the end of last time is cleaned, residual liquid is adsorbed with paper handkerchief.
8, detection antibody is added
(1) 25 μ L 1X detection antibody mixed liquor is added into every hole；
(2) orifice plate is sealed using new sealer；
(3) 96 orifice plates are taken out from Magnetic Isolation plate, shakes 30min as 500rpm room temperature in the plate oscillator of hole.
9, board-washing
(1) 96 orifice plates are placed in Magnetic Isolation plate, stand 2min；
(2) sealer is gently removed, liquid splash is avoided；
(3) the liquid inversion in orifice plate is removed；
(4) 150 μ L 1X Wash Buffer are added into every hole, stand 30s, the liquid inversion in orifice plate are removed, altogether
It washes 3 times；
(5) at the end of last time is cleaned, residual liquid is adsorbed with paper handkerchief.
10, SA-PE is added
(1) 50 μ L SA-PE are added into every hole；
(2) orifice plate is sealed using new sealing film；
(3) 96 orifice plates are taken out from Magnetic Isolation plate, shakes 30min as 500rpm room temperature in the plate oscillator of hole.
11, board-washing
(1) 96 orifice plates are placed in Magnetic Isolation plate, stand 2min；
(2) sealer is gently removed, liquid splash is avoided；
(3) the liquid inversion in orifice plate is removed；
(4) 150 μ L 1X Wash Buffer are added into every hole, stand 30s, the liquid inversion in orifice plate are removed, altogether
It washes 3 times；
(5) at the end of last time is cleaned, residual liquid is adsorbed with paper handkerchief.
12, upper machine testing
(1) 120 μ L Reading Buffer are added into every hole；
(2) orifice plate is sealed using new sealing film；
(3) 96 orifice plates are taken out from Magnetic Isolation plate, shakes 5min as 500rpm room temperature in the plate oscillator of hole；
(4) gently removal seals film, is put into 200 instrument of Bio-Plex and reads.
According to the above method, the pregnant woman and normal labor pregnant and lying-in women to definitive pathological diagnosis after childbirth with Placenta acrreta respectively
The non-anticoagulation cirumferential blood serum acquired before childbirth carries out VEGF-A Concentration Testing.After informed consent, three batches of detections have been carried out altogether
And analysis.The fit standard curve by the way of nonlinear regression, calculates concentration value.Resultant content includes standard curve, every
The fluorescence intensity median in a hole and the concentration calculated according to standard curve.With the detectable concentration of normal labor pregnant and lying-in women
Average value is reference value, calculates separately out detected value/reference value ratio of each suspected case sample.Wherein:
First testing result is as shown in Figs. 1-2, and wherein Fig. 1 is VEGF-A relative concentration, and CON-1 is normal labor motherhood
Woman, PA-1 are the pregnant woman that definitive pathological diagnosis suffers from Placenta acrreta.Fig. 2 is Receiver operating curve (receiver
Operating characteristic curve, abbreviation ROC curve) and its area under the curve AUC value.As the result is shown with 1.0
As cut-off value, to the differentiation performance of pregnant woman and normal labor pregnant woman with moderate strength with Placenta acrreta.
Second batch testing result is as shown in Figure 3-4, and wherein Fig. 3 is VEGF-A relative concentration, and CON-2 is normal labor motherhood
Woman, PA-2 are the pregnant woman that definitive pathological diagnosis suffers from Placenta acrreta.Fig. 4 is ROC curve and its AUC value.As the result is shown using 1.0 as
Cut-off value, to the differentiation performance of pregnant woman and normal labor pregnant woman with moderate strength with Placenta acrreta.
As seen in figs. 5-6, wherein Fig. 5 is VEGF-A relative concentration to third batch testing result, and CON-3 is normal labor motherhood
Woman, PA-3 are the pregnant woman that definitive pathological diagnosis suffers from Placenta acrreta.Fig. 6 is ROC curve and its AUC value.As the result is shown using 1.0 as
Cut-off value, to the differentiation performance of pregnant woman and normal labor pregnant woman with moderate strength with Placenta acrreta.
The statistical result of all three comprehensive batches obtains Testing index as shown in table 1, table 2.
Table 1 is the testing result of all pregnant and lying-in women of threshold value with VEGF-A relative concentration 1.0
The sensibility and specificity that table 2 is detected with VEGF-A relative concentration 1.0
It can be seen from the above result that detection pregnant woman blood in VEGF-A concentration, and with normal pregnancies blood VEGF-A concentration
Compare, using ratio 1.0 as cut-off value, pregnant woman and normal labor pregnant woman for Placenta acrreta have moderate strength
It distinguishes performance (AUC value 0.69, fall between 0.62-0.75), the detection of VEGF-A can be as auxiliary detection pregnant women placental
VEGF-A detection reagent can be applied to the kit of preparation auxiliary detection pregnant women placental implantation by one of means of implantation.
Embodiment 2
It is preceding to childbirth respectively to use other methods diagnostic result for the pregnant of false positive using method same as Example 1
The non-anticoagulation cirumferential blood serum that the pregnant woman that woman and definitive pathological diagnosis merge Placenta acrreta with placental presentation acquires before childbirth,
Carry out VEGF-A Concentration Testing:
Diagnostic result is the pregnant woman of false positive before first group of childbirth are as follows: ultrasound is diagnosed as after placental presentation but childbirth not
The pregnant woman of Placenta acrreta occurs.
Testing result is as Figure 7-8, and wherein Fig. 7 is VEGF-A relative concentration, and P is that ultrasound is diagnosed as placental presentation still
There is no the pregnant woman that Placenta acrreta occurs, PA-3 is that ultrasound is diagnosed as placental presentation while definitive pathological diagnosis is with the pregnant of Placenta acrreta
Woman.Fig. 8 is ROC curve and its AUC value.As the result is shown using 1.0 as cut-off value, to the pregnant woman with Placenta acrreta and divide
There is no the differentiation performances that the pregnant woman that Placenta acrreta occurs has moderate strength after ultrasound is diagnosed as placental presentation but gives a birth before giving birth to.
Diagnostic result is the pregnant woman of false positive before second group of childbirth are as follows: normal labor or other complication occur but simultaneously
There is no the pregnant woman of Placenta acrreta.
As shown in figs. 9-10, wherein Fig. 9 is VEGF-A relative concentration to testing result, and CON+NPA is normal pregnancy or hair
For raw other complication still there is no the pregnant woman of Placenta acrreta, PA is the pregnant woman that definitive pathological diagnosis suffers from Placenta acrreta.Figure 10 is
ROC curve and its AUC value.As the result is shown using 1.0 as cut-off value, to Placenta acrreta pregnant woman and normal labor or
Other complication occur by person but there is no the differentiation performances that the pregnant woman that Placenta acrreta occurs has moderate strength.
Thus, it could be seen that the VEGF-A concentration in detection pregnant woman blood, and compared with normal pregnancies blood VEGF-A concentration,
Pregnant woman for Placenta acrreta and use other methods auxiliary diagnosis result that there is the differentiation of moderate strength for the pregnant woman of false positive
Performance, by this VEGF-A detection reagent be applied to detection Placenta acrreta aided detection method, obtain reference data and and its
The result binding analysis of his method provides a kind of easily and efficiently assistant analysis means, is conducive to improve pregnant women placental implantation
The accuracy of risk profile.
Embodiment 3
According to method described in embodiment 1, after informed consent, 38 normal point of in December, -2017 in January, 2017 is detected
The VEGF-A concentration of the antenatal Peripheral Blood of pregnant and lying-in women is given birth to, obtaining average value is 423.0389, is with reference to normal with this average value
Value calculates detected value/reference value ratio of 10 suspected cases in December, -2017 in January, 2017, obtains result such as 3 institute of table
Show:
Application of the detection of 3 VEGF-A of table in auxiliary diagnosis Placenta acrreta
Each technical characteristic of embodiment described above can be combined arbitrarily, for simplicity of description, not to the above reality
It applies all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, all should be considered as described in this specification.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (10)
1. a kind of kit of auxiliary detection Placenta acrreta, which is characterized in that include the reagent for detecting VEGF-A concentration.
2. kit according to claim 1, which is characterized in that also include VEGF-A standard items.
3. kit according to claim 1 or 2, which is characterized in that the reagent of the detection VEGF-A concentration are as follows:
VEGF-A MBP enzyme linked immuno-adsorbent assay reagent, VEGF-A chemiluminescence immunoassay detection reagent.
4. kit according to claim 3, which is characterized in that the reagent of the detection VEGF-A concentration is Bio-Plex
Assay 171AC600M。
5. a kind of aided detection method of Placenta acrreta, which comprises the following steps:
Sampling: maternal blood sample to be checked is acquired respectively；
It prepares standard curve: using the VEGF-A standard items of the reagent detection gradient concentration of detection VEGF-A concentration, drawing standard
Curve；
Detection: detecting maternal blood sample to be checked using the reagent of detection VEGF-A concentration, by standard curve calculate to
Examine the VEGF-A concentration in maternal blood sample.
6. aided detection method according to claim 5, which is characterized in that further comprising the steps of:
Acquire normal labor peripheral blood sample；
The maternal blood is calculated to obtain using VEGF-A detection reagent detection normal pregnancies peripheral blood sample, by standard curve
VEGF-A concentration in sample；
Calculate the VEGF-A concentration in the VEGF-A concentration and normal pregnancies peripheral blood sample in maternal blood sample to be checked
Ratio.
7. aided detection method according to claim 5, which is characterized in that the sampling are as follows: acquire the non-anticoagulant of pregnant woman
Peripheral blood serum is centrifuged 9~11min in 900 × g~1100 × g, removes blood platelet and sediment.
8. aided detection method according to claim 7, which is characterized in that the sampling are as follows: acquire the non-anticoagulant of pregnant woman
Peripheral blood serum is centrifuged 10min in 1000 × g, removes blood platelet and sediment.
9. according to the described in any item aided detection methods of claim 5~8, which is characterized in that the detection VEGF-A concentration
Reagent are as follows: VEGF-A MBP enzyme linked immuno-adsorbent assay reagent, VEGF-A chemiluminescence immunoassay detection reagent.
10. aided detection method according to claim 9, which is characterized in that it is described detection VEGF-A concentration reagent be
Bio-Plex Assay 171AC600M。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811418592.3A CN109557320A (en) | 2018-11-26 | 2018-11-26 | The kit of auxiliary detection Placenta acrreta and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811418592.3A CN109557320A (en) | 2018-11-26 | 2018-11-26 | The kit of auxiliary detection Placenta acrreta and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109557320A true CN109557320A (en) | 2019-04-02 |
Family
ID=65867177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811418592.3A Pending CN109557320A (en) | 2018-11-26 | 2018-11-26 | The kit of auxiliary detection Placenta acrreta and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109557320A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110938687A (en) * | 2019-12-26 | 2020-03-31 | 余波澜 | Placenta implantation disease marker |
| CN110988352A (en) * | 2019-11-11 | 2020-04-10 | 余波澜 | Kit for auxiliary detection of placenta implantation and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163970A (en) * | 2004-12-21 | 2008-04-16 | 耶鲁大学 | Diagnosis of preeclampsia |
| US20090068679A1 (en) * | 2005-05-09 | 2009-03-12 | Frank Vitzthum | Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof |
| WO2012110483A1 (en) * | 2011-02-15 | 2012-08-23 | Roche Diagnostics Gmbh | Means and methods for diagnosing pregnancy complications based on sflt1 and gdf-15 |
| CN103278633A (en) * | 2013-04-28 | 2013-09-04 | 成都中医药大学 | Kit for screening abortion history of pregnant woman |
| CN104380104A (en) * | 2012-04-24 | 2015-02-25 | 西门子医疗保健诊断公司 | Pre-eclampsia screening methods |
| CN104530234A (en) * | 2014-12-30 | 2015-04-22 | 安源生物科技(上海)有限公司 | Human VEGF detection combination reagent, reagent box and use method thereof |
| CN104711279A (en) * | 2015-03-17 | 2015-06-17 | 北京一达启航生物科技有限公司 | Vascular endothelium growth factor detection kit and raw material preparation |
| CN107121541A (en) * | 2017-04-27 | 2017-09-01 | 龙禹 | Detect purposes and kit, device, screening technique of the CXCL12 reagent in predictive diagnosis MAP kits are prepared |
| CN108717123A (en) * | 2018-04-25 | 2018-10-30 | 卢英 | A kind of method of joint-detection sFlt-1/PLGF and HLA-G detections pre-eclampsia |
| CN108774286A (en) * | 2018-06-28 | 2018-11-09 | 浙江众意生物科技有限公司 | A kind of VEGF-A monoclonal antibodies and kit |
-
2018
- 2018-11-26 CN CN201811418592.3A patent/CN109557320A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163970A (en) * | 2004-12-21 | 2008-04-16 | 耶鲁大学 | Diagnosis of preeclampsia |
| US20090068679A1 (en) * | 2005-05-09 | 2009-03-12 | Frank Vitzthum | Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof |
| WO2012110483A1 (en) * | 2011-02-15 | 2012-08-23 | Roche Diagnostics Gmbh | Means and methods for diagnosing pregnancy complications based on sflt1 and gdf-15 |
| CN104380104A (en) * | 2012-04-24 | 2015-02-25 | 西门子医疗保健诊断公司 | Pre-eclampsia screening methods |
| CN103278633A (en) * | 2013-04-28 | 2013-09-04 | 成都中医药大学 | Kit for screening abortion history of pregnant woman |
| CN104530234A (en) * | 2014-12-30 | 2015-04-22 | 安源生物科技(上海)有限公司 | Human VEGF detection combination reagent, reagent box and use method thereof |
| CN104711279A (en) * | 2015-03-17 | 2015-06-17 | 北京一达启航生物科技有限公司 | Vascular endothelium growth factor detection kit and raw material preparation |
| CN107121541A (en) * | 2017-04-27 | 2017-09-01 | 龙禹 | Detect purposes and kit, device, screening technique of the CXCL12 reagent in predictive diagnosis MAP kits are prepared |
| CN108717123A (en) * | 2018-04-25 | 2018-10-30 | 卢英 | A kind of method of joint-detection sFlt-1/PLGF and HLA-G detections pre-eclampsia |
| CN108774286A (en) * | 2018-06-28 | 2018-11-09 | 浙江众意生物科技有限公司 | A kind of VEGF-A monoclonal antibodies and kit |
Non-Patent Citations (6)
| Title |
|---|
| J.J.TSENG ET AL.: "Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta", 《PLACENTA》 * |
| MARK J.WEHRUM ET AL.: "Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast", 《AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY》 * |
| 余元勋: "《中国分子糖尿病学》", 30 April 2016 * |
| 左琴等: "预测胎盘植入血清学指标研究进展", 《江西医药》 * |
| 张艳等: "彩色多普勒超声检查联合血清VEGF、sFlt-1检测在胎盘植入产前诊断中的应用价值", 《中国妇幼保健》 * |
| 陈焕朝: "《癌症的靶向治疗》", 30 November 2009 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110988352A (en) * | 2019-11-11 | 2020-04-10 | 余波澜 | Kit for auxiliary detection of placenta implantation and application thereof |
| CN110938687A (en) * | 2019-12-26 | 2020-03-31 | 余波澜 | Placenta implantation disease marker |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hanita et al. | Potential use of single measurement of serum progesterone in detecting early pregnancy failure | |
| Wataganara et al. | Placental volume, as measured by 3-dimensional sonography and levels of maternal plasma cell-free fetal DNA | |
| Zhou et al. | Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete | |
| CN109557320A (en) | The kit of auxiliary detection Placenta acrreta and its application | |
| CN109725146A (en) | A kind of purposes and its detection method using serum MMP-1 auxiliary detection | |
| Warrick et al. | Serum activin A does not predict ectopic pregnancy as a single measurement test, alone or as part of a multi-marker panel including progesterone and hCG | |
| Barbosa et al. | Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values | |
| RU2428936C2 (en) | Method of early diagnostics of threatening condition of fetus | |
| Ercan et al. | Neutrophil to Lymphocyte ratio in the diagnosis of adnexal torsion | |
| Sharshiner et al. | Celiac disease serum markers and recurrent pregnancy loss | |
| Kubota et al. | Evaluation of insulin‐like growth factor binding protein‐1 as a diagnostic tool for rupture of the membranes | |
| Li et al. | Predictive value of procalcitonin or c-reactive protein for subclinical intrauterine infection in patients with premature rupture of membranes (PROM) | |
| CN107121541B (en) | The reagent of detection CXCL12 is preparing purposes and kit, device, screening technique in predictive diagnosis MAP kit | |
| Garshasbi et al. | Beta-human chorionic gonadotropin in cervicovaginal secretions and preterm delivery | |
| Husain et al. | Pathological spectrum of endometrial biopsies in Saudi women with abnormal uterine bleeding: A retrospective study of 13-years | |
| Shimada et al. | Sex‐determining region Y levels in maternal plasma: Evaluation in abnormal pregnancy | |
| Wilgen et al. | Hook effect in Abbott i-STAT β-human chorionic gonadotropin (β-hCG) point of care assay | |
| Reimer et al. | Differential diagnosis of peri-and postmenopausal ovarian cysts | |
| Karapetyan et al. | Extracellular DNA in the dynamics of uncomplicated pregnancy | |
| WO2006026243A2 (en) | Inhibin-a: a marker for differentiation, diagnosing and screening abnormal pregnancies | |
| Bischoff et al. | Detection of low‐grade mosaicism in fetal cells isolated from maternal blood | |
| Karakus et al. | The significance of the neutrophil-to-lymphocyte ratio in differential diagnosis of ectopic pregnancy and miscarriage | |
| Kosič et al. | Fetal death from SARS-CoV-2 mediated acute placental failure | |
| CN110988352B (en) | Kit for auxiliary detection of placenta implantation and application thereof | |
| WO2010150804A1 (en) | Method for detection of membrane rupture and amnionic fluid embolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201222 Address after: 510150 Guangdong city in Guangzhou Province, Liwan District Road No. 63 Applicant after: THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL University (GUANGZHOU SEVERE MATERNAL RESCUE CENTER GUANGZHOU ROUJI HOSPITAL) Address before: 510170 No.63 Duobao Road, Liwan District, Guangzhou City, Guangdong Province Applicant before: Yu Bolan Applicant before: Chen Dunjin |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190402 |
|
| RJ01 | Rejection of invention patent application after publication |